Quantum Biopharma Ltd. Files 6-K Report
Ticker: QNTM · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Quantum Biopharma Ltd. (QNTM) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, corporate-update
TL;DR
Quantum Biopharma (fka FSD Pharma) filed a 6-K on Dec 20, 2024. Standard update.
AI Summary
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed a Form 6-K on December 20, 2024. The report is for the month of December 2024 and indicates the company is a foreign private issuer filing under the 1934 Act. The company's principal executive office is located in Toronto, Ontario, Canada.
Why It Matters
This filing provides an update on Quantum Biopharma Ltd.'s regulatory status and corporate information, which is important for investors tracking the company's compliance and reporting.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer information and does not contain significant new financial or operational developments.
Key Players & Entities
- Quantum Biopharma Ltd. (company) — Registrant
- FSD Pharma Inc. (company) — Former company name
- Donal Carroll (person) — Chief Financial Officer
- December 20, 2024 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company makes or is required to make public pursuant to the laws of its home country, or that it files or is required to file with a stock exchange on which it is traded, or that it distributes or is required to distribute to its security holders.
When was Quantum Biopharma Ltd. formerly known as?
Quantum Biopharma Ltd. was formerly known as FSD Pharma Inc., with a date of name change on March 27, 2019.
Who signed the Form 6-K on behalf of Quantum Biopharma Ltd.?
The Form 6-K was signed by Donal Carroll, Chief Financial Officer, on behalf of Quantum Biopharma Ltd.
What is the principal executive office address of Quantum Biopharma Ltd.?
The principal executive office address is 55 University Ave., Suite 1003, Toronto, Ontario M5J2H7, Canada.
What is the SIC code for Quantum Biopharma Ltd.?
The Standard Industrial Classification (SIC) code for Quantum Biopharma Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 140 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-20 09:16:50
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 12KB
- fsd_ex991img2.jpg (GRAPHIC) — 8KB
- 0001654954-24-015776.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Quantum BioPharma Ltd. (Registrant) Date: December 20, 2024 By: /s/ Donal Carroll Donal Carroll, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description Exhibit 99.1 Press Release 3